肿瘤细胞治疗研究
英文原题：The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies.
高级别浆液性卵巢癌（HGSC）预后不良，复发率约为80%，且存在显著化疗耐药。
高级别浆液性卵巢癌（HGSC）预后差，复发率约80%，且存在显著化疗耐药。常规检查点抑制剂疗效有限（10-15%），因此需要替代性免疫治疗策略。工程化T淋巴细胞，尤其是CAR-T和TCR-T细胞，已成为HGSC的有前景策略。本文献综述探讨了工程化T淋巴细胞在HGSC免疫治疗中的有前景作用。在PubMed、Scopus和Cochrane Library数据库中全面检索了2015年至2025年间发表的经同行评议的研究。检索词包括工程化T淋巴细胞、CAR-T细胞、TCR-T细胞、卵巢癌免疫治疗。CAR-T细胞在HGSC中显示出有前景的临床前抗肿瘤活性，高亲和力T细胞克隆显示出强效疗效。工程化T淋巴细胞在多种疾病背景下展现出有前景的方法。在高级别浆液性卵巢癌中，工程化T淋巴细胞通过协调的颗粒酶/穿孔素和Fas/FasL信号传导调控肿瘤细胞凋亡，从而能够快速细胞毒性清除多个肿瘤靶点。
High-grade serous ovarian carcinoma (HGSC) demonstrates poor prognosis with approximately 80% recurrence rates and significant chemotherapy resistance. Conventional checkpoint inhibitors show limited efficacy (10-15%), necessitating alternative immunotherapeutic approaches. Engineered T lymphocytes, particularly CAR-T and TCR-T cells, have emerged as promising strategies for HGSC. This literature review examines the promising role of engineered T lymphocytes in immunotherapy for HGSC. A comprehensive literature search was conducted across PubMed, Scopus, and Cochrane Library databases for peer-reviewed studies published between 2015 and 2025. Search terms included "engineered T lymphocytes," "CAR-T cells," "TCR-T cells," "ovarian cancer immunotherapy". CAR-T cells demonstrate promising preclinical antitumor activity in HGSC, with high-avidity T-cell clones showing robust efficacy. Engineered T lymphocytes demonstrate promising approaches across disease contexts. In high-grade serous ovarian carcinoma, Engineered T lymphocytes orchestrate tumor cell apoptosis through coordinated granzyme/perforin and Fas/FasL signaling, enabling rapid cytotoxic elimination of multiple tumor targets.
MEMBER ACCOUNT
登录成功会直接打开下一页。
